Rosumeck, N.;                     Timmermann, L.;                     Klein, F.;                     Bahra, M.;                     Stintzig, S.;                     Malinka, T.;                     Pelzer, U.    
        Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection? Medicina 2021, 57, 77.
    https://doi.org/10.3390/medicina57010077
    AMA Style
    
                                Rosumeck N,                                 Timmermann L,                                 Klein F,                                 Bahra M,                                 Stintzig S,                                 Malinka T,                                 Pelzer U.        
                Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection? Medicina. 2021; 57(1):77.
        https://doi.org/10.3390/medicina57010077
    
    Chicago/Turabian Style
    
                                Rosumeck, Nathalie,                                 Lea Timmermann,                                 Fritz Klein,                                 Marcus Bahra,                                 Sebastian Stintzig,                                 Thomas Malinka,                                 and Uwe Pelzer.        
                2021. "Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection?" Medicina 57, no. 1: 77.
        https://doi.org/10.3390/medicina57010077
    
    APA Style
    
                                Rosumeck, N.,                                 Timmermann, L.,                                 Klein, F.,                                 Bahra, M.,                                 Stintzig, S.,                                 Malinka, T.,                                 & Pelzer, U.        
        
        (2021). Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma—Who Will Benefit from a Secondary Resection? Medicina, 57(1), 77.
        https://doi.org/10.3390/medicina57010077